Edition:
India

InVivo Therapeutics Holdings Corp (NVIV.OQ)

NVIV.OQ on NASDAQ Stock Exchange Global Market

1.30USD
2:29am IST
Change (% chg)

$0.00 (+0.00%)
Prev Close
$1.30
Open
$1.25
Day's High
$1.30
Day's Low
$1.25
Volume
3,656
Avg. Vol
30,385
52-wk High
$5.40
52-wk Low
$1.10

Chart for

About

InVivo Therapeutics Holdings Corp., formerly Design Source, Inc., is a research and clinical-stage biomaterials and biotechnology company. The Company is engaged in developing and commercializing biopolymer-scaffolding devices for the treatment of spinal cord injuries (SCI). The Company's approach to treating acute SCIs is based... (more)

Overall

Beta: 3.34
Market Cap(Mil.): $53.11
Shares Outstanding(Mil.): 32.18
Dividend: --
Yield (%): --

Financials

Deals of the day-Mergers and acquisitions

Nov 10 The following bids, mergers, acquisitions and disposals were reported by 2100 GMT on Friday:

11 Nov 2017

French agricultural group InVivo to buy garden retailer Jardiland

PARIS French agricultural group InVivo has agreed to buy gardening chain Jardiland to strengthen its position in a sector drawing competitors from do-it-yourself stores to internet distributors.

10 Nov 2017

UPDATE 1-French agricultural group InVivo to buy garden retailer Jardiland

* InVivo faces competition from mass retail, internet (Adds detail, CEO quote)

10 Nov 2017

French agricultural group InVivo to buy gardening retail chain Jardiland

PARIS, Nov 10 French agricultural group InVivo said on Friday it was buying gardening chain Jardiland for an undisclosed amount as it expands its presence in retailing.

10 Nov 2017

BRIEF-InVivo Therapeutics reports Q3 loss per share $0.28

* InVivo Therapeutics provides business update and reports 2017 third quarter financial results

31 Oct 2017

France's InVivo in alliance talks with Jardiland gardening chain

PARIS, Oct 26 French agricultural cooperative InVivo's retail division is in exclusive talks over a potential alliance with gardening retailer Jardiland, the companies said on Thursday.

26 Oct 2017

BRIEF-InVivo Therapeutics Holdings Corp - ‍ expects restructuring to be substantially completed by end of Q3 2017

* InVivo Therapeutics Holdings Corp - ‍ expects restructuring to be substantially completed by end of Q3 2017, to be fully completed by end of Q4 of 2017​

29 Aug 2017

BRIEF-Invivo Therapeutics reports strategic corporate restructuring

* Invivo Therapeutics announces strategic corporate restructuring

29 Aug 2017

BRIEF-InVivo Therapeutics Holdings Q2 adjusted loss per share $0.22 excluding items

* InVivo Therapeutics Holdings provides business update and reports 2017 second quarter financial results

09 Aug 2017

BRIEF-InVivo Therapeutics announces updates on the INSPIRE study

* InVivo Therapeutics Holdings Corp - ‍announces two new patient conversions​

31 Jul 2017

Competitors

Earnings vs. Estimates